Buscar
01/04/2026
Timing of Lung Cancer Diagnosis After Heart Transplantation: Impact of Symptom Status on Stage, Treatment, and Outcomes
Cosio, MG, Severo, A, Gonzalez-Vilchez, F, Lopez-Vilella, R, Bueno, MG, Couto-Mallon, D, Blazquez, Z, Caravaca, P, Alarcos, H, Molina, BD, Romero, EG, Perez, SM, Marquez, MS, Bravo, IG, Tobar, J, Peiro, MB, Muñiz, J, Delgado, J. Timing of Lung Cancer Diagnosis After Heart Transplantation: Impact of Symptom Status on Stage, Treatment, and Outcomes. JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2026; 45(5)DOI:. PMID:. IF:6.000(Q1/1D).
01/04/2026
Profiling Late Right Ventricular Failure Beyond 6 Months Post-LVAD Implantation: Phenotyping, Predictors, and Prognosis
Bofarull, JG, Gallone, G, Thirupathirajan, V, Benedicto, AM, Javier, I, Wypych-Zych, A, Jean-Baptiste, G, Vella, MM, Saez, DG, Shanmuganathan, M, Fiorelli, F, Dar, O, Morley-Smith, A, Gil, FR. Profiling Late Right Ventricular Failure Beyond 6 Months Post-LVAD Implantation: Phenotyping, Predictors, and Prognosis. JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2026; 45(5)DOI:. PMID:. IF:6.000(Q1/1D).
01/04/2026
Hemodynamic Optimization and Hemocompatibility Outcomes in LVAD Recipients
Bofarull, JG, Gallone, G, Thirupathirajan, V, Benedicto, AM, Ibero, J, Topciu, T, Guichard, J, Vella, MM, Saez, DG, Shanmuganathan, M, Fiorelli, F, Dar, O, Morley-Smith, A, Gil, FR. Hemodynamic Optimization and Hemocompatibility Outcomes in LVAD Recipients. JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2026; 45(5)DOI:. PMID:. IF:6.000(Q1/1D).
01/04/2026
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice
Olveira, A, Crespo, J, Ibañez-Samaniego, L, Gallego-Durán, R, Calleja, JL, Aller, R, Soria, A, Gómez-Camarero, J, Martín-Mateos, R, Benlloch, S, Pericàs, JM, Morillas, RM, Bernal-Monterde, V, Diago, M, Turnes, J, Poca, M, Lo Iacono, O, Maya-Miles, D, Escudero, D, Andrade, RJ, Rosales, JM, Jorquera, F, Fernández-Rodriguez, C, Hernández-Guerra, M, Romero-Gómez, M, Ampuero, J. Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice. Clinical Gastroenterology and Hepatology. 2026; 24(4)DOI:10.1016/j.cgh.2025.08.023. PMID:40907848. IF:12.000(Q1/1D).